Please provide your email address to receive an email when new articles are posted on . Direct-to-consumer germline testing for cancer predisposition without oversight and guidance can cause anxiety, ...

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. The subjects were 47 mothers of two or more living children, one ...

New screening tools: Hospitals are piloting tablet-based cognitive exams and AI-driven brain scan analysis to spot Alzheimer’s signs invisible to human observers. Genetic risk insight: Patients can ...

Cancer is the second-leading cause of death in the U.S., and 10% of it comes from inherited gene mutations. Tests for genetic risk factors are inexpensive, and yet many people don't take them. Let's ...

A new editorial was published in Oncotarget's Volume 15 on December 24, 2024, titled "Pitfalls and perils from FDA-approved germ-line cancer predisposition tests." Authored by Dr. Wafik S. El-Deiry, ...

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking ...

People are not taking genetic tests to check for predisposition to certain diseases because their information is being given to insurance companies and impacting their possibility of getting various ...

At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes. The test, which has not undergone FDA clearance and does not ...

An estimated one in every 3,000 people around the globe has neurofibromatosis type 1, or NF1, a condition caused by a mutation in the NF1 gene that carries with it an increased risk of developing ...

Let's say someone in your family has had cancer. Maybe it was even you. How could you find out if the cancer is hereditary and if other members of your family could be at increased risk? The answer?